AI Science Tracker
EN

Program in Applied Biological Sciences

1 discovery from 2024

Discoveries

Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: Random-forest feature selection on measured serum autoantibody profiles identifies a candidate three-antibody iCCA biomarker signature.

Technology: Protein microarrays measured 1,622 proteins in 16 iCCA and 10 matched controls; candidate signatures used leave-one-out cross-validation and were contextualized against tissue-expression data.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Protein microarrays measured 1,622 proteins in 16 iCCA and 10 matched controls; candidate signatures used leave-one-out cross-validation and were contextualized against tissue-expression data.
Limitation / still unknown
Small discovery cohort and internal cross-validation support a candidate biomarker only; no prospective clinical screening utility is shown.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/39198554 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC11358490/unicode · https://pubmed.ncbi.nlm.nih.gov/39198554/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.